/PRNewswire/ Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced.
/PRNewswire/ ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for.
/PRNewswire/ Pathios Therapeutics Limited ("Pathios"), a biotech company focused on developing first-in-class therapies for cancer, today announced that.
Financing led by Brandon Capital from its newly established UK operation; Forbion and Atlas Venture co-led the round USD68M series A will enable London-based.